Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Prostate Cancer

Free Subscription 21.09.2020 1 Acta Radiol 1 AJR Am J Roentgenol 1 Am J Clin Oncol 2 BJU Int 1 BMC Cancer 2 BMC Urol 1 Br J Cancer 1 Br J Radiol 3 Cancer 1 Cancer Lett 2 Cancer Res 2 Clin Cancer Res 3 Clin Imaging 2 Eur Radiol 5 Eur Urol 1 Int J Cancer 6 Int J Radiat Oncol Biol Phys 3 Int J Urol 2 J Clin Oncol 16 J Urol 1 Lancet Oncol 2 N Engl J Med 1 Nat Rev Urol 1 Oncogene 3 PLoS One 1 Prog Urol 3 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Radiol

1. YANG L, Tan Y, Dan H, Hu L, et al
   Diagnostic performance of diffusion-weighted imaging combined with dynamic contrast-enhanced magnetic resonance imaging for prostate cancer: a systematic review and meta-analysis.
   Acta Radiol. 2020 Sep 9:284185120956269. doi: 10.1177/0284185120956269.
   PubMed         Abstract available
   
   

   
   AJR Am J Roentgenol

2. UYSAL A, Karaosmanoglu AD, Karcaaltincaba M, Akata D, et al
   Prostatitis, the Great Mimicker of Prostate Cancer: Can We Differentiate Them Quantitatively With Multiparametric MRI?
   AJR Am J Roentgenol. 2020 Sep 9:1-9. doi: 10.2214/AJR.20.22843.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

3. D'AGOSTINO GR, Mancosu P, Di Brina L, Franzese C, et al
   Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study.
   Am J Clin Oncol. 2020;43:628-635.
   PubMed         Abstract available
   
   

   
   BJU Int

4. CAHILL D
   How the Martini-Klinik handled prostate surgery during COVID-19.
   BJU Int. 2020;126:E1.
   PubMed        
   
   
5. GOLDBERG H, Glicksman R, Woon D, Hoffman A, et al
   Can postreatment free psa ratio be used to predict adverse outcomes in recurrent prostate cancer?
   BJU Int. 2020 Sep 14. doi: 10.1111/bju.15236.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. PRIVE BM, Janssen MJR, van Oort IM, Muselaers CHJ, et al
   Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
   BMC Cancer. 2020;20:884.
   PubMed         Abstract available
   
   

   
   BMC Urol

7. MIYOSHI Y, Kawahara T, Yao M, Uemura H, et al
   Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer.
   BMC Urol. 2020;20:143.
   PubMed         Abstract available
   
   
8. NOVAK V, Vesely S, Luksanova H, Prusa R, et al
   Preoperative prostate health index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer.
   BMC Urol. 2020;20:144.
   PubMed         Abstract available
   
   

   
   Br J Cancer

9. NASTALY P, Stoupiec S, Popeda M, Smentoch J, et al
   EGFR as a stable marker of prostate cancer dissemination to bones.
   Br J Cancer. 2020 Sep 9. pii: 10.1038/s41416-020-01052.
   PubMed         Abstract available
   
   

   
   Br J Radiol

10. ALSHEHRI AHD, Osman SOS, Prise KM, Campfield C, et al
    A novel tool for improving the interpretation of isotope bone scans in metastatic prostate cancer.
    Br J Radiol. 2020 Sep 3:20200775. doi: 10.1259/bjr.20200775.
    PubMed         Abstract available
    
    

    
    Cancer

11. KIM IE JR, Jang TL, Kim S, Modi PK, et al
    Abrogation of survival disparity between black and white individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
    Cancer. 2020 Sep 5. doi: 10.1002/cncr.33179.
    PubMed         Abstract available
    
    
12. CARAM MEV, Oerline MK, Dusetzina S, Herrel LA, et al
    Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
    Cancer. 2020 Sep 14. doi: 10.1002/cncr.33176.
    PubMed         Abstract available
    
    
13. WEN W, Luckenbaugh AN, Bayley CE, Penson DF, et al
    Racial disparities in mortality for patients with prostate cancer after radical prostatectomy.
    Cancer. 2020 Sep 8. doi: 10.1002/cncr.33152.
    PubMed         Abstract available
    
    

    
    Cancer Lett

14. NIKHIL K, Kamra M, Raza A, Shah K, et al
    Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
    Cancer Lett. 2020 Sep 12. pii: S0304-3835(20)30472.
    PubMed         Abstract available
    
    

    
    Cancer Res

15. SHAH N, Kesten N, Font-Tello A, Chang MEK, et al
    ERG-mediated coregulator complex formation maintains androgen receptor signaling in prostate cancer.
    Cancer Res. 2020 Sep 15. pii: 0008-5472.CAN-20-2044.
    PubMed         Abstract available
    
    
16. WANG C, Li J
    A deep learning framework identifies pathogenic noncoding somatic mutations from personal prostate cancer genomes.
    Cancer Res. 2020 Sep 9. pii: 0008-5472.CAN-20-1791.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

17. BORDINI J, Morisi F, Elia AR, Santambrogio P, et al
    Iron induces cell death and strengthens the efficacy of anti-androgen therapy in prostate cancer models.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-3182.
    PubMed         Abstract available
    
    
18. GAO AC, Armstrong CM, Liu C, Liu L, et al
    Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1682.
    PubMed         Abstract available
    
    

    
    Clin Imaging

19. ZHU L, Gao G, Liu Y, Han C, et al
    Feasibility of integrating computer-aided diagnosis with structured reports of prostate multiparametric MRI.
    Clin Imaging. 2020;60:123-130.
    PubMed         Abstract available
    
    
20. TRENT GP, Ye N, Chopra J, Chen R, et al
    Performance of PI-RADS v2 assessment categories assigned prior to MR-US fusion biopsy in a new fusion biopsy program.
    Clin Imaging. 2020;64:29-34.
    PubMed         Abstract available
    
    
21. COLVIN SD, Cason DE, Galgano SJ, Triche BL, et al
    Fusion of high B-value diffusion-weighted and T2-weighted MR images increases sensitivity for identification of extraprostatic disease in prostate cancer.
    Clin Imaging. 2020;68:202-209.
    PubMed         Abstract available
    
    

    
    Eur Radiol

22. KIM CH, Kim CK, Park JJ, Park SY, et al
    Yield of concurrent systemic biopsy during MRI-targeted biopsy according to Prostate Imaging Reporting and Data System version 2 in patients with suspected prostate cancer.
    Eur Radiol. 2020 Sep 10. pii: 10.1007/s00330-020-07167.
    PubMed         Abstract available
    
    
23. HU L, Zhou DW, Fu CX, Benkert T, et al
    Advanced zoomed diffusion-weighted imaging vs. full-field-of-view diffusion-weighted imaging in prostate cancer detection: a radiomic features study.
    Eur Radiol. 2020 Sep 16. pii: 10.1007/s00330-020-07227.
    PubMed         Abstract available
    
    

    
    Eur Urol

24. PACHYNSKI RK
    A "Tail" of Immunotherapy in Metastatic Prostate Cancer.
    Eur Urol. 2020 Sep 12. pii: S0302-2838(20)30691.
    PubMed        
    
    
25. SMITH MR, Saad F, Chowdhury S, Oudard S, et al
    Apalutamide and Overall Survival in Prostate Cancer.
    Eur Urol. 2020 Sep 6. pii: S0302-2838(20)30628.
    PubMed         Abstract available
    
    
26. MIYAMOTO DT, Lee RJ
    PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer.
    Eur Urol. 2020 Sep 5. pii: S0302-2838(20)30684.
    PubMed        
    
    
27. WATERHOUSE JV, Hull JH, Linch M
    Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?
    Eur Urol. 2020;78:9-10.
    PubMed         Abstract available
    
    
28. KELLOKUMPU-LEHTINEN PL, Hjalm-Eriksson M, Thellenberg-Karlsson C, Astrom L, et al
    Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30].
    Eur Urol. 2020 Sep 3. pii: S0302-2838(20)30685.
    PubMed        
    
    

    
    Int J Cancer

29. KARUNAMUNI RA, Huynh-Le MP, Fan CC, Thompson W, et al
    African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33282.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

30. SPRATT DE, Tward JD
    Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
    Int J Radiat Oncol Biol Phys. 2020 Sep 11. pii: S0360-3016(20)31252.
    PubMed        
    
    
31. ROYCE TJ, Mavroidis P, Wang K, Falchook AD, et al
    Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Sep 5. pii: S0360-3016(20)34102.
    PubMed         Abstract available
    
    
32. MOHAMAD O, Roach M 3rd
    Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:337.
    PubMed        
    
    
33. SPRATT DE
    Cancer Treatment Decision-Making During the COVID-19 Pandemic: Data Over Opinion.
    Int J Radiat Oncol Biol Phys. 2020;108:338-339.
    PubMed        
    
    
34. HOFFMAN KE
    Wait and Hurry Up: Radiation Therapy for Prostate Cancer During the COVID-19 Pandemic.
    Int J Radiat Oncol Biol Phys. 2020;108:340.
    PubMed        
    
    
35. LEEMAN JE, Nguyen PL
    Less Is More During COVID 19.
    Int J Radiat Oncol Biol Phys. 2020;108:339.
    PubMed        
    
    

    
    Int J Urol

36. SHIGETA K, Kikuchi E, Matsushima M, Ogihara K, et al
    Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Int J Urol. 2020 Sep 6. doi: 10.1111/iju.14358.
    PubMed         Abstract available
    
    
37. SUGIMURA R, Kawahara T, Uemura H
    Re: Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Sep 13. doi: 10.1111/iju.14371.
    PubMed        
    
    
38. SHIOTA M, Machidori A, Abe T, Monji K, et al
    Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.
    Int J Urol. 2020 Sep 15. doi: 10.1111/iju.14366.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

39. SCHWEIZER MT, Cheng HH, Nelson PS, Montgomery RB, et al
    Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
    J Clin Oncol. 2020 Sep 8:JCO2001755. doi: 10.1200/JCO.20.01755.
    PubMed        
    
    
40. KYRIAKOPOULOS CE, Heath EI, Ferrari A, Sperger JM, et al
    Exploring Spatial-Temporal Changes in (18)F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide.
    J Clin Oncol. 2020 Sep 8:JCO2000348. doi: 10.1200/JCO.20.00348.
    PubMed         Abstract available
    
    

    
    J Urol

41. MORASH C
    Editorial Comment.
    J Urol. 2020;204:279-280.
    PubMed        
    
    
42. NYAME YA
    Editorial Comment.
    J Urol. 2020;204:280.
    PubMed        
    
    
43. CHANDRASEKAR T
    Editorial Comment.
    J Urol. 2020;204:301-302.
    PubMed        
    
    
44. REESE AC
    Editorial Comment.
    J Urol. 2020;204:302.
    PubMed        
    
    
45. EGGENER S
    Editorial Comment.
    J Urol. 2020;204:287.
    PubMed        
    
    
46. CROCEROSSA F, Marchioni M, Novara G, Carbonara U, et al
    Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
    J Urol. 2020 Sep 16:101097JU0000000000001369. doi: 10.1097/JU.0000000000001369.
    PubMed         Abstract available
    
    
47. GIRI VN, Hyatt C, Leader A
    Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice.
    J Urol. 2020 May 27:101097JU0000000000001150. doi: 10.1097/JU.0000000000001150.
    PubMed        
    
    
48. TAN HJ, Zhou X, Spratte BN, McMahon S, et al
    Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer.
    J Urol. 2020 Sep 10:101097JU0000000000001355. doi: 10.1097/JU.0000000000001355.
    PubMed         Abstract available
    
    
49. ABREU AL, Peretsman S, Iwata A, Shakir A, et al
    High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series.
    J Urol. 2020;204:741-747.
    PubMed         Abstract available
    
    
50. FAN L, Fei X, Zhu Y, Pan J, et al
    Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing.
    J Urol. 2020 Sep 8:101097JU0000000000001363. doi: 10.1097/JU.0000000000001363.
    PubMed         Abstract available
    
    
51. DE LA CALLE CM, Fasulo V, Cowan JE, Lonergan PE, et al
    Clinical Utility of 4Kscore, ExosomeDx and Magnetic Resonance Imaging for the Early Detection of High-Grade Prostate Cancer.
    J Urol. 2020 Sep 8:101097JU0000000000001361. doi: 10.1097/JU.0000000000001361.
    PubMed         Abstract available
    
    
52. CHEN Y, Wu X, Yan W
    RE: Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    J Urol. 2020 Sep 8:101097JU0000000000001348. doi: 10.1097/JU.0000000000001348.
    PubMed        
    
    
53. KLEIN EA, Li J, Milinovich A, Schold JD, et al
    Androgen Deprivation Therapy in Men With Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2.
    J Urol. 2020 Sep 8:101097JU0000000000001338. doi: 10.1097/JU.0000000000001338.
    PubMed         Abstract available
    
    
54. PANER GP
    Editorial Comment.
    J Urol. 2020;204:265-266.
    PubMed        
    
    
55. TANEJA SS
    Re: Association of Presalvage Radiotherapy PSA Levels after Prostatectomy with Outcomes of Long-Term Antiandrogen Therapy in Men with Prostate Cancer.
    J Urol. 2020 Sep 8:101097JU0000000000001261. doi: 10.1097/JU.0000000000001261.
    PubMed        
    
    
56. TANEJA SS
    Re: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2020 Sep 8:101097JU000000000000126101.
    PubMed        
    
    

    
    Lancet Oncol

57. FIZAZI K, Kramer G, Eymard JC, Sternberg CN, et al
    Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Lancet Oncol. 2020 Sep 11. pii: S1470-2045(20)30449.
    PubMed         Abstract available
    
    

    
    N Engl J Med

58. FIZAZI K, Shore N, Tammela TL, Ulys A, et al
    Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
    N Engl J Med. 2020;383:1040-1049.
    PubMed         Abstract available
    
    
59. MAHAL BA, Alshalalfa M, Kensler KH, Chowdhury-Paulino I, et al
    Racial Differences in Genomic Profiling of Prostate Cancer.
    N Engl J Med. 2020;383:1083-1085.
    PubMed        
    
    

    
    Nat Rev Urol

60. THOMAS T
    DOT1L in prostate cancer.
    Nat Rev Urol. 2020 Sep 7. pii: 10.1038/s41585-020-0374.
    PubMed        
    
    

    
    Oncogene

61. WEN S, He Y, Wang L, Zhang J, et al
    Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
    Oncogene. 2020 Sep 11. pii: 10.1038/s41388-020-01456.
    PubMed         Abstract available
    
    

    
    PLoS One

62. MISHRA MV, Thayer WM, Janssen E, Hoppe B, et al
    Patient preferences for reducing bowel adverse events following prostate radiotherapy.
    PLoS One. 2020;15:e0235616.
    PubMed         Abstract available
    
    
63. GROARKE A, Curtis R, Skelton J, Groarke JM, et al
    Quality of life and adjustment in men with prostate cancer: Interplay of stress, threat and resilience.
    PLoS One. 2020;15:e0239469.
    PubMed         Abstract available
    
    
64. ALADWANI M, Lophatananon A, Robinson F, Rahman A, et al
    Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study.
    PLoS One. 2020;15:e0238928.
    PubMed         Abstract available
    
    

    
    Prog Urol

65. GOUJON A, Legrand G, Verine J, Hennequin C, et al
    [Active surveillance of prostate cancer: treatement-free survival according to restricted or expanded eligibility criteria].
    Prog Urol. 2020 Sep 12. pii: S1166-7087(20)30109.
    PubMed         Abstract available
    
    

    
    Prostate

66. ZHANG M, Wang Q, Sun X, Yin Q, et al
    beta2 -adrenergic receptor signaling drives prostate cancer progression by targeting the Sonic hedgehog-Gli1 signaling activation.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24060.
    PubMed         Abstract available
    
    
67. NAITO Y, Kato M, Kawanishi H, Yuguchi Y, et al
    The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
    Prostate. 2020 Sep 11. doi: 10.1002/pros.24069.
    PubMed         Abstract available
    
    
68. DUBEY B, Jackson M, Zeigler-Johnson C, Devarajan K, et al
    Interactive effect of TLR SNPs and exposure to sexually transmitted infections on prostate cancer risk in Jamaican men.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24067.
    PubMed         Abstract available
    
    

    
    Urology

69. SHIRK JD
    RE: 3D Printing, Augmented Reality, and Virtual Reality for the Assessment and Management of Kidney and Prostate Cancer: A Systematic Review.
    Urology. 2020 Sep 9. pii: S0090-4295(20)31012.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: